Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.6M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
29M
-
Shares change
-
-586K
-
Total reported value, excl. options
-
$381M
-
Value change
-
-$7.76M
-
Put/Call ratio
-
0.03
-
Number of buys
-
24
-
Number of sells
-
-15
-
Price
-
$13.17
Significant Holders of Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) as of Q4 2022
53 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q4 2022.
Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29M shares
of 59.6M outstanding shares and own 48.58% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.67M shares), FMR LLC (5.61M shares), ORBIMED ADVISORS LLC (2.84M shares), CITADEL ADVISORS LLC (1.85M shares), JANUS HENDERSON GROUP PLC (1.84M shares), BVF INC/IL (1.47M shares), EcoR1 Capital, LLC (1.42M shares), BlackRock Inc. (1.1M shares), VANGUARD GROUP INC (755K shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (701K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.